In this issue:
Sedentary behaviour and risk of type 2 diabetes
Canagliflozin is effective across a range of type 2 diabetes complexities
Effects of canagliflozin on plasma biomarkers of adverse kidney outcomes
Influence of glycaemia during DCCT on future risk of complications during the EDIC study
Benefits of earlier vs later implementation of intensive therapy in type 1 diabetes
Historical HbA1c values may explain the type 2 diabetes legacy effect
Diabetes increases the risk of infection-related hospitalisation
Long-term eye outcomes in the Veteran Affairs Diabetes Trial
Predicting disease progression in pre-symptomatic type 1 diabetes
Time in range and long-term complications in type 1 diabetes
Please login below to download this issue (PDF)